Literature DB >> 16448451

Selecting appropriate management strategies for chronic hepatitis B: who to treat.

Brian J McMahon1.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) infection is a significant problem. In the United States estimates indicate that 0.3% of the population (1.25 million individuals) have chronic hepatitis B infection.
METHODS: Review of published practice guidelines and literature on management of hepatitis B to determine: 1) Which persons in Western populations are at the highest risk for HBV infection and should be screened for HBV seromarkers to identify those who are chronically infected and those who need to be protected with hepatitis B vaccine; 2) The importance of regular monitoring in persons with chronic hepatitis B, the frequency of monitoring, and which tests should be performed; 3) How to identify the patients who are appropriate candidates for antiviral therapy.
RESULTS: Recommendations for screening, diagnosis, monitoring, and treatment of chronic HBV infection are reviewed. Important differences are discussed between the Practice Guidelines for chronic hepatitis B developed by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL). In addition, this article reviews which patients who are no covered by these Guidelines might be candidates for antiviral therapy. DISCUSSION: Established practice guidelines provide direction to providers for the diagnosis and management of chronic HBV infection to reduce the risk of serious sequelae. However, not all patients with chronic hepatitis B are identified, and many of those who are diagnosed do not receive adequate management and follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448451     DOI: 10.1111/j.1572-0241.2006.00446.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Clinical update: hepatitis B.

Authors:  Tram T Tran
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-07

2.  Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

Authors:  David Widjaja; Suresh Yarlagadda; Bheema S Singu; Raghu S Loganathan; Steve Blum; Alan Bloom; Prospere Remy
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

3.  Current management and recommendations on hepatitis B therapy in HIV-coinfected patients.

Authors:  Lionel Piroth; Sophie Mahy; Stanislas Pol; Fabrice Carrat; Damien Sene; Manuel Etienne; Caroline Lascoux-Combe; Anne Simon; Jean-Luc Schmit; Patrice Cacoub
Journal:  Hepatol Int       Date:  2011-07-15       Impact factor: 6.047

4.  Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies.

Authors:  George Lau; Patrick Marcellin; Marion Peters
Journal:  Hepatol Int       Date:  2007-06-06       Impact factor: 6.047

5.  Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.

Authors:  EunYoung Ze; Eun Kyung Baek; Jong Jin Lee; Han Wook Chung; Dae Geon Ahn; Hwan Jun Cho; Jae Cheol Kwon; Hyung Joon Kim; HyunWoong Lee
Journal:  Clin Mol Hepatol       Date:  2014-09-25

6.  Hepatitis B virus DNA level Among the Seropositive Afghan Immigrants, Southern Iran.

Authors:  Mohammad Amin Behzadi; Mazyar Ziyaeyan; Sadaf Asaei
Journal:  Jundishapur J Microbiol       Date:  2014-05-01       Impact factor: 0.747

7.  Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.

Authors:  Min Lian; Xu Zhou; Lai Wei; Shihong Qiu; Tong Zhou; Lanfen Li; Xiaocheng Gu; Ming Luo; Xiaofeng Zheng
Journal:  Virol J       Date:  2007-09-24       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.